In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles

Table 1 Clinical data of rheumatoid arthritis patients used in functional assays

	Gender	Age (years)	Disease duration (years)	CRP (mg/l)	RF (IU/ml)	ACPA (IU/ml)	DAS28	ESR (mm/h)	Treatment	β60-74 ELISA ratio
Patient 1	Female	54	5	8.1	264	1971	4.99	15	Sal, Afl, Lefl	10.26
Patient 2	Female	55	6	8.2	265	1971	4.1	16	Sal, Afl, Lefl	11.26
Patient 3	Female	78	9	1.84	16.2	2410	3.7	10	MTX	15.26
Patient 4	Female	82	12	2.1	10.9	Neg.	5.05	47	MTX, Med	0.89
Patient 5	Female	62	8	0.41	293.6	2403	2.17	21	Trexan	0.94
Patient 6	Male	45	6	0.7	47	3200	0.63	2	Del, Trexan	0.74
Patient 7	Female	52	4	3.1	264.1	3200	4.09	29	MTX, Med	6.59
Patient 8	Female	71	7	2.3	15	1759	2.83	19	MTX, Med	7.41
Patient 9	Female	39	6	0.5	96.2	3073	2.06	3	MTX	14.81
Patient 10	Female	45	3	1.9	394.5	295	1.1	3	MTX, Med	9.97
Patient 11	Female	43	3	2.5	10.3	952	1.05	6	Imuran, Metoject	7.65
Patient 12	Male	75	12	37.8	51.5	3200	2.5	4	Med, MTX	6.55
Patient 13	Male	74	19	0.14	360.9	2403	0.84	5	Roactemrat	13.8
Patient 14	Female	45	5	4.64	74.4	2991	4.01	9	Medrol, Trexan	20.97
Patient 15	Female	64	7	3.1	15.6	951	2.22	13	Lefl, Med	3.58
Patient 16	Female	63	5	6.7	673	964	2.1	20	Sal, Metoject	9.56
Patient 17	Male	70	9	9.3	25	3200	2.63	5	MTX, Sal, Med	14.35
Patient 18	Female	76	24	19.7	225	2132	7.97	42	Med, MTX	8.31
Patient 19	Female	41	1	2.3	129	765	3.41	4	Med	6.98
Patient 20	Female	60	9	47.86	65.3	349	5.39	97	Med, Nebivolol	6.35

ACPA anti-citrullinated protein antibodies, Afl aflamin, CRP C-reactive protein, DAS28 Disease Activity Score of 28 joints, Del delagil, ELISA enzyme-linked immunosorbent assay, ESR erythrocyte sedimentation rate, Lefl leflunomid, Med medrol, MTX methotrexate, Neg negative, RF rheumatoid factor, Sal salazopyrin

ISSN: 1478-6362